Joseph C Papa bought $350K of Emergent BioSolutions (EBS)
Executed May 13 2025, disclosed May 15 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (May 15 2025), the stock returned +11.4% (delay-adjusted); from the execution session (May 13 2025), +12.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Joseph C Papa (President and CEO) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Emergent BioSolutions Inc. (EBS). Across 1 priced purchase filing, the average 21-session return was +12.7% from execution and +11.4% from disclosure (delay-adjusted; derived). The largest single filing was $350K of EBS (60,000 sh × $5.83, as filed), executed May 13 2025.
Healthcare · Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→